Tylenol maker Kenvue said on Monday that Johnson & Johnson will offload its entire 9.5% stake in the company, about a year ...
J&J finalized the biggest shake-up in its 137-year history to focus on its pharmaceutical and medical devices businesses. The ...
, opens new tab will sell its remaining 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer health business. Based on Kenvue stock's last ...
Un año después del spin-off de su negocio de consumo, Johnson & Johnson anunció hoy que venderá lo que queda de su participación en Kenvue. Ofrecerá sus 182,33 millones de acciones restantes por deuda ...
Tylenol maker Kenvue has said that Johnson & Johnson will sell its remaining 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer health business.
En un comunicado remitido a la Comisión de Bolsa y Valores de Estados Unidos (SEC), Kenvue ha informado de que se espera que Johnson & Johnson intercambie 182,32 millones de acciones ordinarias ...
(Reuters) – Tylenol maker Kenvue said on Monday that Johnson & Johnson will offload its entire 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its ...